What do systematic reviews say?

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Mucositis (all grades)
  Mucositis all grades: not estimable due to high heterogeneity (P=0.0009; I2=86%) between subgroups (cetuximab; nimotuzumab) and within cetuximab (I2=93%); 1417 participants, 3 studies. Table 3, row 1.6 (Ang 2014;…
  3 studies · 1417 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Skin toxicity/acneiform rash (cetuximab, all grades)
  RR 6.56 [5.35, 8.03]
  2 studies · 1311 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Xerostomia (grades >=3)
  RR 1.36 [0.80, 2.31]
  2 studies · 1311 participants
  GRADE not reported

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… showed no clear difference in progression-free survival compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Monoclonal antibody + chemoradiotherapy vs chemoradiotherapy alone
  HR 1.08 [0.89, 1.32]
  1 study · 891 participants
  GRADE not reported
• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months · Monoclonal antibody + radiotherapy vs radiotherapy alone
  HR 0.70 [0.54, 0.91]
  1 study · 424 participants
  GRADE not reported

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

The review found no eligible studies for this question.

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  No included studies addressed participant satisfaction (review-wide gap).
  0 studies
  No studies found

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

The review found no eligible studies for this question.

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  No included studies addressed direct and indirect costs to participants and health services (review-wide gap).
  0 studies
  No studies found

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower overall survival compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  HR 0.82 [0.69, 0.97]
  3 studies · 1421 participants
  Moderate

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard… probably leads to lower locoregional control compared with standard therapy alone (radiotherapy or chemoradiotherapy) (moderate certainty).

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  HR 0.68 [0.52, 0.89]
  1 study · 424 participants
  Moderate

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  Only one study (Bonner 2006, 424 participants) comprehensively assessed quality of life using EORTC QLQ-C30 (v3.0) and QLQ-H&N35; no statistically significant difference between groups for global health status or any…
  1 study · 424 participants
  GRADE not reported

Antibody (T cell) vs steroids

Antibody (T cell) probably leads to lower failure of reversal of acute rejection compared with steroid (stratified by antibody type) (moderate certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.5 [0.3, 0.82]
  6 studies · 405 participants
  Moderate

Antibody (T cell) vs steroids

Antibody (T cell) showed no clear difference in recurrent rejection compared with steroid (stratified by antibody type) (moderate certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.75 [0.56, 1]
  9 studies · 508 participants
  Moderate

Antibody (T cell) vs steroids

Antibody (T cell) showed no clear difference in graft loss or death with a functioning graft compared with steroid (stratified by antibody type) (low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.84 [0.58, 1.22]
  8 studies · 490 participants
  Low

Antibody (T cell) vs steroids

Antibody (T cell) showed no clear difference in graft loss censored for death compared with steroid (stratified by antibody type) (low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.8 [0.57, 1.12]
  8 studies · 475 participants
  Low

Antibody (T cell) vs steroids

It is very uncertain whether antibody (T cell) changes death compared with steroid (stratified by antibody type) (very low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.98 [0.51, 1.88]
  7 studies · 413 participants
  Very low

Antibody (T cell) vs steroids

It is very uncertain whether antibody (T cell) changes treatment adverse events: fever, chill, or malaise after drug… compared with steroid (stratified by antibody type) (very low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 23.88 [5.1, 111.86]
  4 studies · 280 participants
  Very low

Antibody (T cell) + steroid vs steroids

It is very uncertain whether antibody (T cell) + steroid changes graft loss censored for death compared with steroid alone (very low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.33 [0.03, 4.16]
  2 studies · 50 participants
  Very low

Antibody (T cell) + steroid vs steroids

Antibody (T cell) + steroid showed no clear difference in death compared with steroid alone (low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.86 [0.53, 1.39]
  2 studies · 50 participants
  Low

Antibody (T cell) + steroid vs steroids

Antibody (T cell) + steroid showed no clear difference in failure of reversal of acute rejection episode compared with steroid alone (low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.42 [0.17, 1.01]
  1 study · 30 participants
  Low

Antibody (T cell) + steroid vs steroids

Antibody (T cell) + steroid showed no clear difference in recurrent rejection compared with steroid alone (low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.07 [0, 1.06]
  1 study · 30 participants
  Low

Antibody (T cell) + steroid vs steroids

It is very uncertain whether antibody (T cell) + steroid changes graft loss or death with a functioning graft compared with steroid alone (very low certainty).

• Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only
  RR 0.35 [0.02, 5.14]
  2 studies · 52 participants
  Very low